Cellerys AG
- Address
- Wagistrasse 21
Sponsor Overview
Specializations
Multiple Sclerosis
Cellerys AG focuses on relapsing remitting multiple sclerosis, with clinical activity centered on the treatment of autoimmune demyelinating disease affecting the central nervous system. The sponsor’s research interest is directed toward patients living with recurrent inflammatory disease activity and neurological impairment.
- Relapsing remitting multiple sclerosis
- Autoimmune central nervous system disease
- Inflammatory demyelination
The clinical program reflects a concentrated therapeutic interest in neurology and neuroimmunology, with attention to disease control in a chronic relapsing condition.
Neuroimmunology
The sponsor’s research landscape includes immune-mediated mechanisms relevant to multiple sclerosis, particularly the interaction between the immune system and nervous tissue. This area supports investigation of therapies aimed at modifying pathological immune responses in neurological disease.
- Immune-mediated neurological disease
- Central nervous system inflammation
- Autoimmune pathology
Clinical interest extends to therapeutic strategies that address immune dysregulation in chronic neurologic conditions.
Safety and Tolerability
Cellerys AG is engaged in clinical evaluation of treatment safety and tolerability in people with RRMS. This area is relevant to understanding how investigational therapies are received in patients with ongoing neurologic disease and immune activation.
- Safety assessment
- Tolerability
- Patient treatment experience
The sponsor’s clinical focus includes monitoring of adverse effects and treatment acceptability in a chronic neurological disorder.
Cell-Based and Peptide-Linked Therapeutics
The trial portfolio indicates interest in cell-based therapeutic approaches and peptide-coupled treatment concepts for multiple sclerosis. This places the sponsor within an area of translational research that combines immunological targeting with advanced therapeutic design.
- Cell-based therapy
- Peptide-linked treatment concepts
- Immune-targeted intervention
These interests align with development in novel immunotherapies for neurological autoimmune disease.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Safety and Efficacy of CLS12311 in Patients with Relapsing Remitting Multiple Sclerosis: A Phase Ib/IIa Multicenter Study |  Czechia Germany Italy | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 18 sites across their trial portfolio.
Therapeutic Focus
- 1.Nervous System Diseases1 trial449 other sponsors
Partnered Research Centres
18 centres- Address
- Via Nicolo' Giustiniani 2, 35128 Padua
- Address
- Largo Giovanni Alessandro Brambilla 3, 50134 Florence
- Address
- Via Di Grottarossa 1035-1039, 00189 Rome
- Address
- Hindenburgdamm 30, Lichterfelde, 12203 Berlin
- Address
- Sokolska 581, Novy Hradec Kralove, 500 03 Novy Hradec Kralove
- Address
- Srobarova 1150/50, Vinohrady, 100 00 Prague
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Cellerys AG.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.